Clinical trial
ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
NCT00436072 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00436072 |
|---|---|
| Title | ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer |
| Official title | Phase I Study of ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Beth Israel Deaconess Medical Center AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | ZD6474, Cetuximab, Irinotecan |
| Enrollment | 46 |
| Start date | Feb 1, 2007 |
| Primary completion | Feb 1, 2012 |
| Completion | Aug 1, 2012 |
| First posted | Feb 16, 2007 |
| Last update posted | Oct 4, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: